Your fact-checks will appear here
The safety of GLP-1 receptor agonists, including potential links to blindness and paralysis
The short answer: are not proven to directly cause widespread blindness or generalized paralysis, but credible signals and lawsuits tie these drugs to rare, sometimes severe vision-threatening conditi...
Clinical trials and systematic reviews consistently document clinically meaningful metabolic and weight rebound after stopping GLP‑1 receptor agonists, and while commentators and reviews urge “structu...
No reporting in the documents provided contains clinical trial data or safety analyses that explicitly evaluate adverse events tied to a commercial supplement called "Gelatide"; the sources instead in...
Food‑triggered endogenous GLP‑1 is a short‑acting, meal‑linked gut and brain signal that contributes to satiety and meal termination, while pharmacologic GLP‑1 receptor agonists (GLP‑1 RAs) are long‑a...
Social media narratives that brand supplements, diets, or unregulated products as “natural Ozempic” have blurred public understanding of GLP‑1 receptor agonists by equating complex, prescription-only ...